Zobrazeno 1 - 10
of 108
pro vyhledávání: '"Masanori Toyoda"'
Autor:
Chiaki Suzuki, Naomi Kiyota, Yoshinori Imamura, Hideaki Goto, Hirotaka Suto, Naoko Chayahara, Masanori Toyoda, Yasuhiro Ito, Akihiro Miya, Akira Miyauchi, Masanori Teshima, Naoki Otsuki, Ken-ichi Nibu, Hironobu Minami
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundWe previously reported that a high tumor burden is a prognostic factor based on an analysis of 26 patients with radioactive iodine-refractory differentiated thyroid cancer (RR-DTC) who were treated with lenvatinib. However, the optimal tumo
Externí odkaz:
https://doaj.org/article/0472ad3ccd2646a489bf7c687870b4b0
Autor:
Hiroko Yamada, Takuji Kurimoto, Sotaro Mori, Mari Sakamoto, Kaori Ueda, Yuko Yamada-Nakanishi, Yoichi Uozumi, Hiroyasu Shose, Masaaki Taniguchi, Masanori Toyoda, Hironobu Minami, Makoto Nakamura
Publikováno v:
Case Reports in Ophthalmology, Vol 10, Iss 3, Pp 319-326 (2019)
Langerhans cell histiocytosis (LCH) is characterised by tissue destruction caused by the abnormal proliferation of pathogenic dendritic cells. We report a rare case of multi-system LCH with local invasion of the orbital apex.A 56-year-old woman suffe
Externí odkaz:
https://doaj.org/article/0c6fb309f30c425885e5ca2666f5785d
Autor:
Yasuko Hyogo, Naomi Kiyota, Naoki Otsuki, Shunsuke Goto, Yoshinori Imamura, Naoko Chayahara, Masanori Toyoda, Ken-ichi Nibu, Toshiki Hyodo, Shigeo Hara, Hiroo Masuoka, Toshihiko Kasahara, Yasuhiro Ito, Akihiro Miya, Mitsuyoshi Hirokawa, Akira Miyauchi, Hironobu Minami
Publikováno v:
Case Reports in Oncology, Vol 11, Iss 3, Pp 735-741 (2018)
Standard therapy for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) is multi-targeted kinase inhibitors (m-TKIs), represented by sorafenib and lenvatinib. One of the main target molecules of m-TKIs is vascular endothelial gro
Externí odkaz:
https://doaj.org/article/b0d0c9d7672e45e898a65b676b42e0c5
Mediastinal Germ Cell Tumor Exhibiting a Discrepancy between Tumor Markers and Imaging: A Case Study
Autor:
Kei Takenaka, Toru Mukohara, Chihoko Hirai, Yohei Funakoshi, Yukiko Nakamura, Naoko Chayahara, Masanori Toyoda, Naomi Kiyota, Tomoo Itoh, Hiroshi Yokozaki, Hironobu Minami
Publikováno v:
Case Reports in Oncology, Vol 8, Iss 2, Pp 323-331 (2015)
We report a mediastinal germ cell tumor (GCT) that exhibited a discrepancy between the time course of serum human chorionic gonadotropin (hCG) levels and clinical consequences. An otherwise healthy man, aged 34 years, was diagnosed with a nonseminoma
Externí odkaz:
https://doaj.org/article/542ff648486e4c60972697d909b0d50b
Autor:
Yutaka Fujiwara, Shogo Kobayashi, Hiroaki Nagano, Masashi Kanai, Etsuo Hatano, Masanori Toyoda, Tetsuo Ajiki, Yuki Takashima, Kenichi Yoshimura, Akinobu Hamada, Hironobu Minami, Tatsuya Ioka
Publikováno v:
PLoS ONE, Vol 10, Iss 12, p e0143072 (2015)
Biliary tract cancer (BTC) patients who have undergone surgical resection with major hepatectomy cannot tolerate the standard gemcitabine regimen (1,000 mg/m2 on days 1, 8, and 15 every 4 weeks) due to severe toxicities such as myelosuppression. Our
Externí odkaz:
https://doaj.org/article/a21bacafa4cf41e981593a6b03cf9fa3
Autor:
Yutaka Fujiwara, Takashi Kobayashi, Naoko Chayahara, Yoshinori Imamura, Masanori Toyoda, Naomi Kiyota, Toru Mukohara, Shin Nishiumi, Takeshi Azuma, Masaru Yoshida, Hironobu Minami
Publikováno v:
PLoS ONE, Vol 9, Iss 11, p e113259 (2014)
Cancer cachexia is a multifactorial syndrome characterized by progressive loss of weight and muscle atrophy. Using metabolomics, we investigated serum markers and their intra-day variation in advanced pancreatic cancer patients with cachexia.Patients
Externí odkaz:
https://doaj.org/article/8071ee0bdc66431c914808ce05f8cc71
Autor:
Yutaka Fujiwara, Masanori Toyoda, Naoko Chayahara, Naomi Kiyota, Takanobu Shimada, Yoshinori Imamura, Toru Mukohara, Hironobu Minami
Publikováno v:
PLoS ONE, Vol 9, Iss 8, p e104215 (2014)
PURPOSE: Oxycodone is a µ-opioid receptor agonist widely used in the treatment of cancer pain. The predominant metabolic pathway of oxycodone is CYP3A4-mediated N-demethylation to noroxycodone, while a minor proportion undergoes 3-O-demethylation to
Externí odkaz:
https://doaj.org/article/0a282b5555004faa8cb5049a8333da2f
Autor:
Tatsuya, Ioka, Masashi, Kanai, Shogo, Kobayashi, Daisuke, Sakai, Hidetoshi, Eguchi, Hideo, Baba, Satoru, Seo, Akinobu, Taketomi, Tadatoshi, Takayama, Hiroki, Yamaue, Masahiro, Takahashi, Masayuki, Sho, Keiko, Kamei, Jiro, Fujimoto, Masanori, Toyoda, Junzo, Shimizu, Takuma, Goto, Yoshitaro, Shindo, Kenichi, Yoshimura, Etsuro, Hatano, Hiroaki, Nagano
Publikováno v:
Journal of Hepato-Biliary-Pancreatic Sciences. 30:102-110
Gemcitabine/cisplatin (GC) combination therapy has been the standard palliative chemotherapy for patients with advanced biliary tract cancer (BTC). No randomized clinical trials have been able to demonstrate the survival benefit over GC during the pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43be00fb662687fa5cdd916b00eb7d65
https://doi.org/10.1002/jhbp.1219
https://doi.org/10.1002/jhbp.1219
Autor:
Hironobu Minami, Yoshimi Fujishima, Sho Nishimura, Masanori Toyoda, Naomi Kiyota, Taiji Koyama, Yoshinori Imamura, Yohei Funakoshi, Hirokazu Tanino
Publikováno v:
Internal Medicine. 60:3485-3488
Treatment with anti-programmed cell death-1 (PD-1) antibodies improves the anti-cancer immune response and can provide a meaningful clinical benefit to cancer patients. However, this treatment can result in specific autoimmune toxicities, termed immu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0da3a4f15135ed419b3a959fae17e822
https://doi.org/10.2169/internalmedicine.6550-20
https://doi.org/10.2169/internalmedicine.6550-20
Autor:
Scott Cameron, Ayako Mitsuma, Yoichi Naito, Tomoya Shimokata, Yuichi Ando, Takeshi Tajima, Kae Ishihara, Nobuaki Matsubara, Yoshinori Imamura, Hironobu Minami, Kota Tokushige, Toshihiko Doi, Naomi Kiyota, Masanori Toyoda
Publikováno v:
Cancer Science
Spartalizumab is a humanized IgG4/κ mAb directed against human programmed cell death‐1 (PD‐1). In this phase I study, we investigated safety, pharmacokinetics, preliminary antitumor activity, and toxicity of spartalizumab in patients with advanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db60d64d2ef3d78d42de85360ea1f805
http://www.lib.kobe-u.ac.jp/handle_kernel/90007885
http://www.lib.kobe-u.ac.jp/handle_kernel/90007885